Kenbe, you are spot on. Diversification is the key

Kenbe, you are spot on. Diversification is the key. I know there is, and rightly so, a lot of excitement for the compounding pharmacy stream of revenue. The potential is incredible, and with the addition of more 1099 reps out there, will blow our minds. But what makes SCRC a solid investment is Bob has developed other streams of business to impact the bottom line. I believe once RapiMeds hits full force in China and Canada, the combined revenues will stun us all. Most of the big pharma companies aren't successful because one product, its a combination of their entire product line. I love what Bob has put together here and am ready to see the bottom line soar each month. GO SCRC!!!